Aralez Pharmaceuticals Company Profile (NASDAQ:ARLZ)

About Aralez Pharmaceuticals (NASDAQ:ARLZ)

Aralez Pharmaceuticals logoAralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:ARLZ
  • CUSIP: 73941U10
  • Web:
  • Market Cap: $106.96 million
  • Outstanding Shares: 66,848,000
Average Prices:
  • 50 Day Moving Avg: $1.72
  • 200 Day Moving Avg: $1.46
  • 52 Week Range: $0.95 - $5.49
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.36
  • P/E Growth: -0.03
Sales & Book Value:
  • Annual Revenue: $87.22 million
  • Price / Sales: 1.18
  • Book Value: $1.12 per share
  • Price / Book: 1.38
  • EBITDA: ($55,020,000.00)
  • Net Margins: -122.35%
  • Return on Equity: -90.17%
  • Return on Assets: -22.15%
  • Debt-to-Equity Ratio: 3.66%
  • Current Ratio: 1.11%
  • Quick Ratio: 1.04%
  • Average Volume: 796,778 shs.
  • Beta: 1.52
  • Short Ratio: 4.84

Frequently Asked Questions for Aralez Pharmaceuticals (NASDAQ:ARLZ)

What is Aralez Pharmaceuticals' stock symbol?

Aralez Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARLZ."

How were Aralez Pharmaceuticals' earnings last quarter?

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) announced its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.01. The firm had revenue of $27.62 million for the quarter, compared to the consensus estimate of $21.37 million. Aralez Pharmaceuticals had a negative return on equity of 90.17% and a negative net margin of 122.35%. The business's revenue for the quarter was up 119.6% compared to the same quarter last year. During the same quarter last year, the business earned ($0.27) earnings per share. View Aralez Pharmaceuticals' Earnings History.

When will Aralez Pharmaceuticals make its next earnings announcement?

Aralez Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Aralez Pharmaceuticals.

Where is Aralez Pharmaceuticals' stock going? Where will Aralez Pharmaceuticals' stock price be in 2017?

2 equities research analysts have issued 1-year price targets for Aralez Pharmaceuticals' stock. Their predictions range from $4.00 to $4.00. On average, they expect Aralez Pharmaceuticals' stock price to reach $4.00 in the next year. View Analyst Ratings for Aralez Pharmaceuticals.

Who are some of Aralez Pharmaceuticals' key competitors?

Who are Aralez Pharmaceuticals' key executives?

Aralez Pharmaceuticals' management team includes the folowing people:

  • Arthur S. Kirsch, Independent Chairman of the Board
  • Andrew Ian Koven, President, Chief Business Officer
  • Adrian Adams, Chief Executive Officer, Director
  • Scott J. Charles, Chief Financial Officer, Senior Vice President
  • Jennifer Lou Armstrong, Executive Vice President - Human Resources and Administration
  • Eric L. Trachtenberg, Chief Compliance Officer, General Counsel, Corporate Secretary
  • Mark A. Glickman, Chief Commercial Officer
  • James Patrick Tursi M.D., Chief Medical Officer
  • Kenneth B. Lee Jr., Lead Independent Director
  • Neal Franklin Fowler, Independent Director

How do I buy Aralez Pharmaceuticals stock?

Shares of Aralez Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aralez Pharmaceuticals' stock price today?

One share of Aralez Pharmaceuticals stock can currently be purchased for approximately $1.54.

MarketBeat Community Rating for Aralez Pharmaceuticals (NASDAQ ARLZ)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  229
MarketBeat's community ratings are surveys of what our community members think about Aralez Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aralez Pharmaceuticals (NASDAQ:ARLZ) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.00 (159.74% upside)
Consensus Price Target History for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Price Target History for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Analysts' Ratings History for Aralez Pharmaceuticals (NASDAQ:ARLZ)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017Chardan CapitalLower Price TargetBuy -> Buy$5.50 -> $4.00HighView Rating Details
4/10/2017Bloom BurtonUpgradeAccumulate -> BuyMediumView Rating Details
10/10/2016GuggenheimSet Price TargetBuy$12.00N/AView Rating Details
3/16/2016Dundee SecuritiesLower Price TargetBuy$10.00 -> $9.00N/AView Rating Details
(Data available from 10/19/2015 forward)


Earnings History for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Earnings by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Earnings History by Quarter for Aralez Pharmaceuticals (NASDAQ ARLZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017N/AView Earnings Details
8/9/20176/30/2017($0.41)($0.42)$21.37 million$27.62 millionViewListenView Earnings Details
5/9/20173/31/2017($0.40)($0.42)$20.23 million$26.00 millionViewListenView Earnings Details
3/13/201712/31/2016($0.26)($0.37)$21.86 million$20.00 millionViewListenView Earnings Details
11/7/2016Q316($0.32)($0.32)$12.23 million$136.00 millionViewListenView Earnings Details
8/9/2016Q216($0.19)($0.27)$9.70 million$12.60 millionViewListenView Earnings Details
5/10/2016Q116($0.53)($0.73)$9.70 million$8.10 millionViewListenView Earnings Details
3/15/2016Q415($0.28)($0.40)$9.25 million$5.97 millionViewListenView Earnings Details
11/9/2015Q315($0.26)($0.25)$5.20 million$5.80 millionViewListenView Earnings Details
8/10/2015Q215$0.04($0.50)$4.60 million$5.20 millionViewListenView Earnings Details
5/8/2015Q115$0.08$0.01$4.70 million$4.40 millionViewListenView Earnings Details
3/9/2015Q414$0.17$0.21$8.55 million$9.90 millionViewListenView Earnings Details
11/6/2014Q314$0.11$0.20$7.50 million$7.50 millionViewListenView Earnings Details
8/7/2014Q214$0.05$0.09$7.10 million$7.40 millionViewListenView Earnings Details
5/8/2014Q1($0.06)$0.09$5.50 million$7.55 millionViewListenView Earnings Details
3/5/2014Q413($0.05)($0.07)$4.35 million$4.70 millionViewListenView Earnings Details
11/6/2013Q313($0.09)($0.16)$3.25 million$2.60 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.20)($0.13)$1.30 million$1.70 millionViewListenView Earnings Details
5/8/2013Q1 2013($0.19)($0.19)$1.43 million$1.40 millionViewListenView Earnings Details
3/6/2013Q4 2012($0.21)($0.20)$1.46 million$1.40 millionViewListenView Earnings Details
11/8/2012Q312($0.15)($0.19)$2.73 million$0.90 millionViewN/AView Earnings Details
8/1/2012($0.25)($0.17)ViewN/AView Earnings Details
5/1/2012($0.28)($0.28)ViewN/AView Earnings Details
2/28/2012$2.00$2.04ViewN/AView Earnings Details
11/3/2011($0.24)($0.24)ViewN/AView Earnings Details
7/28/2011($0.19)($0.21)ViewN/AView Earnings Details
5/5/2011($0.23)($0.19)ViewN/AView Earnings Details
3/9/2011$0.56$0.61ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Aralez Pharmaceuticals (NASDAQ:ARLZ)
2017 EPS Consensus Estimate: ($1.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.48)($0.48)($0.48)
Q2 20171($0.43)($0.43)($0.43)
Q3 20171($0.46)($0.46)($0.46)
Q4 20171($0.46)($0.46)($0.46)
(Data provided by Zacks Investment Research)


Dividend History by Quarter for Aralez Pharmaceuticals (NASDAQ ARLZ)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 23.79%
Insider Trades by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Institutional Ownership by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Insider Trades by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017James Patrick TursiInsiderSell9,960$2.50$24,900.00View SEC Filing  
7/28/2017Scott J CharlesCFOSell10,804$1.25$13,505.00View SEC Filing  
6/23/2017Eric TrachtenbergInsiderSell7,720$1.33$10,267.60View SEC Filing  
6/15/2017Arthur S KirschDirectorBuy15,000$1.15$17,250.00View SEC Filing  
6/14/2017Arthur S KirschDirectorBuy50,000$1.17$58,500.00View SEC Filing  
6/5/2017Andrew I KovenInsiderSell161,906$1.28$207,239.68View SEC Filing  
5/23/2017Jason AryehDirectorSell388,685$1.44$559,706.40View SEC Filing  
3/20/2017Andrew I KovenInsiderSell7,825$2.41$18,858.25View SEC Filing  
3/20/2017Scott J CharlesCFOSell5,205$2.41$12,544.05View SEC Filing  
3/15/2017Adrian AdamsCEOBuy500,000$2.46$1,230,000.00View SEC Filing  
3/15/2017Arthur S KirschDirectorBuy45,000$2.27$102,150.00View SEC Filing  
3/15/2017James Patrick TursiInsiderBuy4,750$2.11$10,022.50View SEC Filing  
11/29/2016Robert Paul HarrisDirectorSell104,778$4.99$522,842.22View SEC Filing  
11/28/2016Robert Paul HarrisDirectorSell20,000$4.65$93,000.00View SEC Filing  
11/14/2016Kenneth B Lee JrDirectorBuy1,000$4.95$4,950.00View SEC Filing  
11/11/2016Seth RudnickDirectorBuy30,000$4.77$143,100.00View SEC Filing  
9/15/2016Robert Paul HarrisDirectorSell150,000$5.82$873,000.00View SEC Filing  
5/20/2016James Patrick TursiInsiderBuy10,000$3.75$37,500.00View SEC Filing  
5/16/2016Eric TrachtenbergInsiderBuy10,000$3.76$37,600.00View SEC Filing  
5/13/2016Kenneth B Lee JrDirectorBuy1,000$3.50$3,500.00View SEC Filing  
5/12/2016Andrew I KovenInsiderBuy71,500$3.49$249,535.00View SEC Filing  
5/12/2016Arthur S KirschDirectorBuy27,500$3.49$95,975.00View SEC Filing  
5/12/2016Scott J CharlesCFOBuy50,000$3.49$174,500.00View SEC Filing  
12/3/2015John R PlachetkaMajor ShareholderSell23,479$8.14$191,119.06View SEC Filing  
11/13/2015John R PlachetkaMajor ShareholderSell150,000$7.00$1,050,000.00View SEC Filing  
11/12/2015Adrian AdamsCEOBuy1,000,000$6.55$6,550,000.00View SEC Filing  
9/10/2015John E. BarnhardtVPSell18,322$8.78$160,867.16View SEC Filing  
6/18/2015John G FortInsiderSell78,905$10.93$862,431.65View SEC Filing  
6/3/2015Gilda Marie ThomasInsiderSell23,555$7.53$177,369.15View SEC Filing  
4/15/2015Gilda Marie ThomasInsiderSell25,000$8.61$215,250.00View SEC Filing  
3/17/2015Gilda Marie ThomasInsiderSell50,000$7.51$375,500.00View SEC Filing  
1/2/2015Gilda Marie ThomasVPSell25,000$7.91$197,750.00View SEC Filing  
12/1/2014Par Investment Partners LpMajor ShareholderBuy500,000$7.50$3,750,000.00View SEC Filing  
11/18/2014John R PlachetkaCEOSell50,000$9.00$450,000.00View SEC Filing  
11/6/2014John R PlachetkaCEOSell50,000$9.08$454,000.00View SEC Filing  
10/9/2014John R PlachetkaCEOSell50,000$8.12$406,000.00View SEC Filing  
10/8/2014John R PlachetkaCEOSell32,227$8.16$262,972.32View SEC Filing  
9/30/2014John R PlachetkaCEOSell50,000$7.48$374,000.00View SEC Filing  
9/29/2014John R PlachetkaCEOSell38,298$7.53$288,383.94View SEC Filing  
9/15/2014Dennis L McnamaraEVPSell4,275$7.85$33,558.75View SEC Filing  
9/9/2014John R PlachetkaCEOSell50,000$8.24$412,000.00View SEC Filing  
9/8/2014John R PlachetkaCEOSell30,000$8.30$249,000.00View SEC Filing  
8/25/2014John E BarnhardtVPSell4,293$8.25$35,417.25View SEC Filing  
8/20/2014John R PlachetkaCEOSell50,000$7.78$389,000.00View SEC Filing  
8/8/2014John R PlachetkaCEOSell50,000$7.75$387,500.00View SEC Filing  
7/30/2014John R PlachetkaCEOSell50,000$7.34$367,000.00View SEC Filing  
7/9/2014John R PlachetkaCEOSell50,000$8.88$444,000.00View SEC Filing  
7/8/2014John R PlachetkaCEOSell33,551$8.87$297,597.37View SEC Filing  
7/2/2014William L HodgesCFOSell11,414$9.05$103,296.70View SEC Filing  
6/23/2014John E BarnhardtVPSell27,484$8.80$241,859.20View SEC Filing  
6/23/2014William L HodgesCFOSell5,688$9.05$51,476.40View SEC Filing  
6/20/2014William L HodgesCFOSell50,000$9.05$452,500.00View SEC Filing  
6/19/2014William L HodgesCFOSell9,516$9.05$86,119.80View SEC Filing  
6/17/2014William L HodgesCFOSell112,156$9.03$1,012,768.68View SEC Filing  
6/16/2014Dennis L McnamaraEVPSell15,100$9.06$136,806.00View SEC Filing  
6/11/2014Arthur S KirschDirectorSell9,430$9.30$87,699.00View SEC Filing  
6/5/2014Arthur S KirschDirectorSell2,500$8.67$21,675.00View SEC Filing  
6/2/2014Arthur S KirschDirectorSell2,500$8.73$21,825.00View SEC Filing  
5/27/2014Arthur S KirschDirectorSell10,000$8.38$83,800.00View SEC Filing  
5/22/2014John BarnhardtVPSell77,840$8.31$646,850.40View SEC Filing  
5/16/2014John FortInsiderSell4,000$8.49$33,960.00View SEC Filing  
5/16/2014William HodgesCFOSell71,003$8.16$579,384.48View SEC Filing  
4/24/2014John FortInsiderSell13,725$9.61$131,897.25View SEC Filing  
12/20/2013John FortInsiderSell22,500$9.63$216,675.00View SEC Filing  
7/17/2013Par Investment Partners LpMajor ShareholderBuy90,000$5.25$472,500.00View SEC Filing  
12/27/2012John E BarnhardtVPSell5,219$5.25$27,399.75View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Latest Headlines for Aralez Pharmaceuticals (NASDAQ:ARLZ)
DateHeadline logoJames Patrick Tursi Sells 9,960 Shares of Aralez Pharmaceuticals Inc. (ARLZ) Stock - October 4 at 10:42 PM logoAralez Pharmaceuticals (ARLZ) & Cadence Pharmaceuticals (CADX) Critical Comparison - September 29 at 6:24 AM logoOutside the Box: Trump’s tax plan is one big step from reality - September 28 at 10:24 PM logoOutside the Box: Why the Trump tax plan’s fuzzy math​ doesn’t add up - September 26 at 4:56 PM logoAnalyzing Aralez Pharmaceuticals (ARLZ) and The Competition - September 11 at 2:24 AM logoContrasting Eli Lilly and (LLY) and Aralez Pharmaceuticals (ARLZ) - September 7 at 2:20 PM logoETFs with exposure to Aralez Pharmaceuticals, Inc. : September 5, 2017 - September 5 at 10:42 PM logoRecent Developments in the Pharmaceutical Industry - September 5 at 5:38 PM logoOutside the Box: Here’s how Republicans and Democrats can come together to fix health care - August 23 at 6:10 AM logoEli Lilly and (LLY) versus Aralez Pharmaceuticals (ARLZ) Head to Head Analysis - August 10 at 2:38 PM logoAralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Price Target Cut to $4.00 by Analysts at Chardan Capital - August 10 at 2:16 PM logoEdited Transcript of ARLZ earnings conference call or presentation 9-Aug-17 1:00pm GMT - August 9 at 9:15 PM logoAralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Releases Earnings Results, Misses Expectations By $0.01 EPS - August 9 at 3:24 PM logoAralez Pharmaceuticals Inc (NASDAQ:ARLZ) to Release Earnings on Wednesday - August 2 at 7:10 AM logoAralez Pharmaceuticals Inc. (ARLZ) CFO Sells $13,505.00 in Stock - July 28 at 7:50 PM logoAralez: A Quick Overview Of The Investment Thesis - Seeking Alpha - July 25 at 8:57 PM logoShould You Be Worried About Your Heartburn Medication Causing Dementia? - July 22 at 3:38 AM logoAralez Pharmaceuticals Inc. (ARLZ) Short Interest Update - July 16 at 7:06 AM logoARLZ: Promising Early Data Following Launch of Zontivity®; VIMOVO® Patents Upheld - July 10 at 9:04 PM logoAralez Pharmaceuticals (ARLZ) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow - June 8 at 4:21 PM logoAralez Pharma (ARLZ) Launchs Zontivity in the US - - June 7 at 3:47 PM logoForm 4 Aralez Pharmaceuticals For: May 11 Filed by: Armstrong Jennifer Lou - May 13 at 2:44 AM logoAralez Pharmaceuticals reports 1Q loss - May 9 at 8:59 AM logoAralez Announces Voting Results From 2017 Annual And Special Meeting Of Shareholders - PR Newswire (press release) - May 3 at 8:41 PM logoAralez Pharma (ARLZ) to Reduce Workforce by 32% as Part of Cost Savings Program - - April 7 at 8:04 AM logoWhy Did Aralez's CEO Buy 500,000 Shares On March 15? - March 27 at 3:43 PM logoAralez Pharmaceuticals (ARLZ): Adrian Adams CEO Purchased 500,000 Shares Last Week: An Update And Interview - March 25 at 8:36 PM logoARALEZ PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E - March 23 at 10:04 PM logoAralez Pharmaceuticals' (ARLZ) CEO Adrian Adams on Q4 2016 Results - Earnings Call Transcript - March 14 at 3:32 PM logoMid-Day Market Update: AMEC Foster Wheeler Surges Following Wood Group Bid; Aralez Pharmaceuticals Shares ... - Benzinga - March 14 at 5:49 AM logoWhy Aralez Pharmaceuticals Inc. Got Slaughtered Today - March 13 at 4:00 PM logoBUZZ-US STOCKS ON THE MOVE-Intel, Kronos, Aethlon, Aralez, Ciber - Nasdaq - March 13 at 3:43 PM logoMid-Day Market Update: AMEC Foster Wheeler Surges Following Wood Group Bid; Aralez Pharmaceuticals Shares ... - Nasdaq - March 13 at 3:43 PM logoAralez Pharmaceuticals Inc Earnings Call scheduled for 9:00 am ET today - March 13 at 3:43 PM logoAralez Reports Fourth Quarter And Full-Year 2016 Financial Results - March 13 at 8:34 AM logoARALEZ PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosu - March 13 at 8:34 AM logoQ4 2016 Aralez Pharmaceuticals Inc Earnings Release - Before Market Open - March 13 at 8:34 AM logoARALEZ PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement - March 2 at 3:51 PM logoAralez Pharmaceuticals (ARLZ) Presents at RBC Capital Markets Global Healthcare Conference 2017-Slideshow - February 22 at 8:38 PM logoOutside the Box: Trump’s tax reform looks like just another of his tweets - February 16 at 7:54 PM logoAralez Pharmaceuticals Inc. (Nasdaq: ARLZ) to Ring The Nasdaq Stock Market Closing Bell - Nasdaq - February 14 at 9:18 PM logoResearch Reports Coverage on Biotech Stocks -- Cerulean Pharma, AveXis, TG Therapeutics, and Aralez Pharma - PR Newswire (press release) - February 8 at 3:52 PM logoPremarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen - - January 27 at 9:34 PM logoARALEZ PHARMACEUTICALS INC. Files SEC form 8-K, Other Events - January 27 at 4:32 PM logoAralez Announces Issuance Of Additional U.S. Patent For Yosprala - January 11 at 3:52 PM logoAralez Pharma (ARLZ) Submits MMA for PA10040 in Europe - - January 10 at 3:40 PM logoAralez Pharma (ARLZ) Submits MMA for PA10040 in Europe - January 9 at 3:55 PM logoAralez Pharmaceuticals (ARLZ) Dips on Product Launch - December 19 at 3:55 PM logoAralez Announces Commercial Launch Of BLEXTEN™ In Canada - December 19 at 3:55 PM



Aralez Pharmaceuticals (ARLZ) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.